ProKidney Corp.

NASDAQ:PROK

Biotechnology

Healthcare
$1.04 +0.86%

+$0.02 today

Market cap
$349.70M
Beta
1.70
P/E (TTM)
-3.3
EPS (TTM)
-$0.53
52W Low $0.54High $7.13

Volume 1.80M

Average 0.96M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$120.12M

FY 2025 · Annual

Investing Cash Flow

$103.97M

FY 2025 · Annual

+409.3% YoY

Financing Cash Flow

$25.57M

FY 2025 · Annual

-82.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(55.15M)(148.14M)(135.45M)(163.34M)(151.61M)
Depreciation & Amortization1.98M3.04M3.85M5.43M6.58M
Deferred Income Tax00000
Stock-Based Compensation699K74.47M30.85M29.37M25.34M
Change in Working Capital2.16M(6.46M)16.67M3.96M1.28M
Accounts Receivables00(1.38M)(1.07M)1.32M
Inventory00000
Accounts Payables5K494K11.64M11.59M(5.92M)
Other Working Capital2.16M(6.95M)6.41M(6.56M)5.88M
Other Non-Cash Items00(6M)(1.78M)(1.7M)
Operating Cash Flow(50.3M)(77.09M)(90.07M)(126.35M)(120.12M)
Capital Expenditures(5.19M)(1.85M)(34.2M)(29.51M)(15.2M)
Acquisitions (Net)1K108K0018.22M
Purchases of Investments00(471.6M)(324.02M)(217.08M)
Sales of Investments00175.82M373.95M318.02M
Other Investing Activities00000
Investing Cash Flow(5.19M)(1.74M)(329.98M)20.41M103.97M
Debt Repayment(30K)(32K)(52K)(54K)(26K)
Common Stock Issued71.5M6.05M0144.32M25.6M
Common Stock Repurchased00(9.5M)00
Dividends Paid00000
Other Financing Activities0542.5M0140K0
Financing Cash Flow71.47M548.52M(9.55M)144.41M25.57M
Effect of Forex Changes00000
Net Change in Cash15.98M469.69M(429.6M)38.47M9.42M
Free Cash Flow(55.49M)(78.94M)(124.27M)(155.86M)(135.31M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$151.6M
+ D&A$6.6M
+ Stock-Based Comp$25.3M
+ Deferred Tax$0
+ Working Capital$1.3M
- Other Non-Cash-$1.7M
= Operating Cash Flow-$120.1M
- Capex-$15.2M
= Free Cash Flow-$135.3M

Analysis

FY2025 free cash flow is -$135.3M. FCF conversion is 89.2% of net income. Operating cash flow was -$120.1M, with capex of -$15.2M. The largest bridge item is Stock-Based Comp at $25.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
424B5424B5 filingNov 12, 2026
8-KCurrent reportNov 12, 2026
EFFECTEFFECT filingNov 10, 2026
8-KCurrent reportNov 9, 2026

Does PROK generate free cash flow?

ProKidney Corp. (PROK) generated -$135.31M of free cash flow in fiscal 2025.

How much operating cash flow does PROK produce?

Operating cash flow was -$120.12M, before capital expenditures of $15.20M.